--- title: "Weekly Recap | Vor BioPharma -10.98%, phase 3 enrolment complete" type: "News" locale: "en" url: "https://longbridge.com/en/news/298796676.md" description: "Vor BioPharma fell 10.98% this week to close at $22.30. The S&P 500 slipped 0.8% over the same stretch, leaving the stock about 10.18 percentage points behind the benchmark. The week opened on Tuesday (8 Sep) at $24.75, touched an intraday high of $26.00, then faded to close at $25.10. Wednesday pulled back to $23.24, Thursday slipped to $22.34, and Friday settled at $22.30. Full-week amplitude was 15.8%, with 3.17m shares traded across four sessions and a daily average of 0." datetime: "2026-09-12T07:12:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298796676.md) - [en](https://longbridge.com/en/news/298796676.md) - [zh-HK](https://longbridge.com/zh-HK/news/298796676.md) generator: "portal-rs" --- # Weekly Recap | Vor BioPharma -10.98%, phase 3 enrolment complete ## The Week Vor BioPharma fell 10.98% this week to close at $22.30. The S&P 500 slipped 0.8% over the same stretch, leaving the stock about 10.18 percentage points behind the benchmark. The week opened on Tuesday (8 Sep) at $24.75, touched an intraday high of $26.00, then faded to close at $25.10. Wednesday pulled back to $23.24, Thursday slipped to $22.34, and Friday settled at $22.30. Full-week amplitude was 15.8%, with 3.17m shares traded across four sessions and a daily average of 0.79m, slightly below the 60-day median of 0.85m. On the latest trading day, large-lot money was a net buyer at 48.30%, while small and mid orders combined showed net selling of roughly 101.07%. ## Key Events The main company-specific development was completion of enrolment in the Phase 3 UPSTREAM MG trial for telitacicept in generalised myasthenia gravis. The company also flagged this BAFF/APRIL inhibitor as its lead programme in B cell-driven autoimmune diseases. Both items hit after the close on 8 Sep; the following session saw the stock fall 7.4%. The same batch included macro pieces on sector rotation and cross-border capital flow divergence, but these carry limited direct read-through for the company. A 10 Sep article noting a 5.4% single-day drop is price-action commentary rather than a standalone event. ## Analyst Ratings Nine brokers cover the name: seven rate it buy, one overweight, and one hold, with no underperform or sell ratings. The consensus recommendation is strong buy, with a consensus target of $39, about 74.9% above the current price of $22.30. Targets range from $27 to $50, pointing to a wide dispersion. Within the biotechnology industry, the stock ranks 152nd among 506 names, against a median of six and a mean of seven covering brokers. ## The Week Ahead The macro calendar is back-loaded into 15–16 Sep: Tuesday brings the New York Fed Empire State manufacturing index (prior 20.6, forecast 14.75), and Wednesday features retail sales ex-autos, retail control, import prices, the NAHB housing market index, and weekly EIA crude inventories. These prints will shape rate expectations and could feed into the valuation environment for growth names. On the company side, no data-readout date for UPSTREAM MG appears in the calendar, so watch for further announcements from Vor Bio. ## In Short The week holds a tension: a Phase 3 enrolment milestone and a strongly bullish analyst consensus with a target 74.9% above spot sit against a stock that lost over 10% and lagged the market by 10 percentage points. The current P/E is 2.1x, book value per share is negative, and the latest session shows large-lot buying against small-and-mid net selling. The question ahead is whether pipeline progress can win back capital amid next week’s macro-heavy calendar. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [VOR.US](https://longbridge.com/en/quote/VOR.US.md) ## Related News & Research - [Vor Bio says telitacicept Phase 3 analysis shows 42% minimal symptom expression in gMG through 48 weeks](https://longbridge.com/en/news/300433508.md) - [Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | VOR Stock News](https://longbridge.com/en/news/300433546.md) - [Greg Abel-Led Berkshire Hathaway Owns 3 Consumer Stocks. Here's the One I'd Buy First.](https://longbridge.com/en/news/300873098.md) - [NVIDIA Corporation $NVDA Stock Sold by Quartz Partners LLC](https://longbridge.com/en/news/300872368.md) - [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**